PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33199994-8	2020	DMF also increased the activity of the nuclear factor erythroid 2-related factor (Nrf) 2/heme oxygenase (HO)-1 signaling pathway in NP cells and increased the phosphorylation of Akt.	Dimethyl Fumarate	0-3	AKT serine/threonine kinase 1	Homo sapiens	178-181	
33199994-9	2020	DMF also increased the anti-inflammatory and antioxidative ability of NP cells by promoting the activity of the Nrf2/HO-1 and PI3K/Akt signaling pathways, thus delaying IVDD.	Dimethyl Fumarate	0-3	AKT serine/threonine kinase 1	Homo sapiens	131-134	
32816241-6	2020	PI3K substrate Akt (at Ser473) as well as Wnt dependent beta-catenin and cyclin D1 activity was found to be upregulated by DMF pretreatment in Abeta1-42 treated cells.	Dimethyl Fumarate	123-126	AKT serine/threonine kinase 1	Homo sapiens	15-18	
32816241-9	2020	These results indicate that down-regulation of GSK-3beta activity and subsequent activation of PI3K/Akt and Wnt/beta-catenin signaling pathways are closely involved in the shielding effect of DMF against Abeta1-42-induced tau hyperphosphorylation.	Dimethyl Fumarate	192-195	AKT serine/threonine kinase 1	Homo sapiens	100-103	
28870693-10	2018	Together, our work demonstrates a mechanism of the antifibrotic effect of DMF via inhibition of Akt1/GSK3beta/TAZ/YAP signaling and confirms a critical role of TAZ/YAP in mediating the profibrotic responses in dermal fibroblasts.	Dimethyl Fumarate	74-77	AKT serine/threonine kinase 1	Homo sapiens	96-100	
35141161-0	2022	Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy via Inhibiting the Hippo/YAP, NRF2-ARE, and AKT/mTOR/ERK Pathways in A375 Melanoma Cells.	Dimethyl Fumarate	0-17	AKT serine/threonine kinase 1	Homo sapiens	120-123	
28870693-4	2018	Mechanistically, we found that DMF treatment reduced nuclear localization of transcriptional coactivator with PDZ binding motif (TAZ) and Yes-associated protein (YAP) proteins via inhibition of the phosphatidylinositol 3 kinase/protein kinase B (Akt) pathway.	Dimethyl Fumarate	31-34	AKT serine/threonine kinase 1	Homo sapiens	246-249	
28870693-5	2018	In addition, DMF abrogated TGFbeta/Akt1 mediated inhibitory phosphorylation of glycogen kinase 3beta (GSK3beta) and a subsequent beta-transducin repeat-containing proteins (betaTRCP) mediated proteasomal degradation of TAZ, as well as a corresponding decrease of TAZ/YAP transcriptional targets.	Dimethyl Fumarate	13-16	AKT serine/threonine kinase 1	Homo sapiens	35-39	
33922540-4	2021	The results suggest that polymorphisms detected in the GSTP1, ITGA4, NQO1, AKT1, and GP6 genes, for treatment with natalizumab, ZMIZ1, for fingolimod and dimethyl fumarate, ADA, for cladribine, and NOX3, for dimethyl fumarate, may be used in the future as predictive markers of treatment response to new therapies in MS patients.	Dimethyl Fumarate	154-171	AKT serine/threonine kinase 1	Homo sapiens	75-79	
33922540-4	2021	The results suggest that polymorphisms detected in the GSTP1, ITGA4, NQO1, AKT1, and GP6 genes, for treatment with natalizumab, ZMIZ1, for fingolimod and dimethyl fumarate, ADA, for cladribine, and NOX3, for dimethyl fumarate, may be used in the future as predictive markers of treatment response to new therapies in MS patients.	Dimethyl Fumarate	208-225	AKT serine/threonine kinase 1	Homo sapiens	75-79